Base de dados : MEDLINE
Pesquisa : C01.252.825 [Categoria DeCS]
Referências encontradas : 3455 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 346 ir para página                         

  1 / 3455 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384903
[Au] Autor:De Anda C; Anuskiewicz S; Prokocimer P; Vazquez J
[Ad] Endereço:Merck & Co., Inc., Kenilworth, NJ, USA.
[Ti] Título:Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials.
[So] Source:Medicine (Baltimore);96(52):e9163, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Acute bacterial skin and skin structure infections (ABSSSI) are a frequent cause of hospital admissions in the United States. Safe and effective outpatient treatments may lower ABSSSI-associated health care costs by reducing unnecessary hospital admissions. Using data from 2 phase 3 trials (ESTABLISH-1, NCT01170221; ESTABLISH-2, NCT01421511), this post-hoc analysis explored the efficacy and safety of tedizolid in an outpatient setting. METHODS: Subgroup analysis was performed on US outpatients (defined as patients who were not in hospital at the time of treatment initiation) with ABSSSI caused by presumed or proven gram-positive pathogens. Patients were randomly assigned to receive tedizolid phosphate 200 mg once daily for 6 days (n = 403) or linezolid 600 mg twice daily for 10 days (n = 410). The primary end point was early clinical response (48-72 hours after the start of treatment). Secondary end points included investigator-assessed clinical response at end of therapy (EOT) and post-therapy evaluation (PTE; 7-14 days after therapy). Additional assessments included the patient-reported level of pain using a visual analog scale (VAS) and the per-pathogen favorable microbiological response rate at the PTE visit. Compliance with treatment and safety outcomes was also recorded. RESULTS: Early clinical response was similar between treatment groups (tedizolid, 82.4%; linezolid, 79.0%), as was investigator-assessed clinical response at EOT (tedizolid, 87.1%; linezolid, 86.1%) and PTE (tedizolid, 83.1%; linezolid, 83.7%). Mean changes from baseline to days 10 to 13 in VAS scores were identical between treatment groups (tedizolid, -51.9 mm; linezolid, -51.9 mm). Microbiological eradication rates were generally similar in both treatment groups for all key pathogens. Patients in both groups had favorable response at PTE. More tedizolid-treated patients (89.3%) than linezolid-treated patients (77.3%) were compliant with treatment. The most frequently reported drug-related treatment-emergent adverse events were nausea (tedizolid, 10.7%; linezolid, 13.8%), diarrhea (tedizolid, 4.5%; linezolid, 5.9%), and headache (tedizolid, 5.5%; linezolid, 4.4%). Treatment discontinuation rates were low for both treatment groups (tedizolid, 0.7%; linezolid, 1.0%). CONCLUSION: Short-course therapy with tedizolid can successfully treat patients with ABSSSI caused by presumed or proven gram-positive pathogens in an outpatient setting.
[Mh] Termos MeSH primário: Assistência Ambulatorial
Antibacterianos/uso terapêutico
Linezolida/uso terapêutico
Organofosfatos/uso terapêutico
Oxazóis/uso terapêutico
Dermatopatias Bacterianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Dermatopatias Bacterianas/patologia
Resultado do Tratamento
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Organophosphates); 0 (Oxazoles); ISQ9I6J12J (Linezolid); O7DRJ6R4DW (torezolid phosphate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009163


  2 / 3455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29258361
[Au] Autor:Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
[Ad] Endereço:a Department of Dermatology , University of Rome 'Tor Vergata ,' Rome , Italy.
[Ti] Título:Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
[So] Source:Expert Opin Drug Metab Toxicol;14(2):197-206, 2018 Feb.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Acute bacterial skin and skin structure infections (ABSSIs), defined as a bacterial infection of the skin with a lesion size area of at least 75 cm, are a leading cause of hospital admission and ambulatory care visits worldwide. Dalbavancin is a lipoglycopeptide antibiotic recently approved by the United States Food and Drug Administration (FDA) and by European Medicines Agency (EMA) for ABSSSIs. The authors review and provide updates of efficacy and safety by several studies on dalbavancin. Areas covered: A PubMed search was performed for relevant literature. We especially focused our attention on pharmacokinetics. Expert opinion: Dalbavancin provides an important new therapy for management of ABSSI, maintaining a spectrum of activity similar to vancomycin against gram-positive organisms. Use of dalbavancin, with its 1-week-shot treatment, consist in a reduction of the length of hospital stay or in a reduction of hospital admissions, with important cost savings.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Dermatopatias Bacterianas/tratamento farmacológico
Teicoplanina/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Antibacterianos/economia
Antibacterianos/farmacocinética
Redução de Custos
Infecções por Bactérias Gram-Positivas/tratamento farmacológico
Infecções por Bactérias Gram-Positivas/economia
Infecções por Bactérias Gram-Positivas/microbiologia
Hospitalização/estatística & dados numéricos
Seres Humanos
Tempo de Internação
Dermatopatias Bacterianas/economia
Dermatopatias Bacterianas/microbiologia
Teicoplanina/administração & dosagem
Teicoplanina/economia
Teicoplanina/farmacocinética
Vancomicina/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 61036-62-2 (Teicoplanin); 6Q205EH1VU (Vancomycin); 808UI9MS5K (dalbavancin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2018.1420162


  3 / 3455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29254311
[Au] Autor:Jagmag T; Tirant M; Lotti T
[Ad] Endereço:The Dent-All Clinic, Mumbai, India.
[Ti] Título:Link between cutaneous infection, stress and depression.
[So] Source:J Biol Regul Homeost Agents;31(4):1037-1041, 2017 Oct-Dec.
[Is] ISSN:0393-974X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Depression and mood disorders often develop after dermatological conditions which could be primary or secondary to dermatological pathology. The oxidative and psychological stress cause physiological changes in the body. Shift in the methylation pathway, elevated cortisol, lowered neurotransmitter levels and lowered immune system allow infection to penetrate the body and lead to anxiety and depression. Here, a case report of a 20 year old male patient is presented to show how infectious skin lesions, unresponsive to the usual treatment plan, were treated after using a multipronged approach of addressing systemic infection of Escherichia coli, elevated cortisol levels and nutritional imbalances.
[Mh] Termos MeSH primário: Ansiedade/psicologia
Depressão/psicologia
Infecções por Escherichia coli/psicologia
Dermatopatias Bacterianas/psicologia
Estresse Psicológico/psicologia
[Mh] Termos MeSH secundário: Antibacterianos/uso terapêutico
Ansiedade/complicações
Ansiedade/tratamento farmacológico
Ansiedade/microbiologia
Cefoperazona/uso terapêutico
Depressão/complicações
Depressão/tratamento farmacológico
Depressão/microbiologia
Infecções por Escherichia coli/complicações
Infecções por Escherichia coli/tratamento farmacológico
Infecções por Escherichia coli/microbiologia
Seres Humanos
Hidrocortisona/sangue
Masculino
Fosfatidilserinas/uso terapêutico
Probióticos/uso terapêutico
Dermatopatias Bacterianas/complicações
Dermatopatias Bacterianas/tratamento farmacológico
Dermatopatias Bacterianas/microbiologia
Estresse Psicológico/complicações
Estresse Psicológico/tratamento farmacológico
Estresse Psicológico/microbiologia
Sulbactam/uso terapêutico
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Phosphatidylserines); 7U75I1278D (Cefoperazone); S4TF6I2330 (Sulbactam); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE


  4 / 3455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29293307
[Au] Autor:O'Bright NE
[Ti] Título:Packing versus non-packing outcomes for abscesses after incision and drainage.
[So] Source:J Okla State Med Assoc;110(2):78-9, 2017 02.
[Is] ISSN:0030-1876
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CLINICAL QUESTION: In non-diabetic, non-immunocompromised individuals with skin abscesses, does packing after incision and drainage (I&D) reduce the risk of recurrence or reintervention compared with not packing? ANSWER: No. If the abscess is less than 5 cm, packing does not affect outcomes. LEVEL OF EVIDENCE FOR THE ANSWER: B. DATE SEARCH WAS CONDUCTED: November 2014. INCLUSION CRITERIA: Published RCTs and meta-analysis studies. EXCLUSION CRITERIA: Abscess greater than 5 cm, abscess in diabetics, abscess in immunocompromised.
[Mh] Termos MeSH primário: Abscesso/cirurgia
Cuidados Pós-Operatórios/métodos
Dermatopatias Bacterianas/cirurgia
[Mh] Termos MeSH secundário: Abscesso/patologia
Bandagens
Drenagem
Seres Humanos
Dermatopatias Bacterianas/patologia
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180103
[St] Status:MEDLINE


  5 / 3455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28450145
[Au] Autor:Zhao-Fleming H; Dissanaike S; Rumbaugh K
[Ad] Endereço:Departments of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX, United States; Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
[Ti] Título:Are anaerobes a major, underappreciated cause of necrotizing infections?
[So] Source:Anaerobe;45:65-70, 2017 Jun.
[Is] ISSN:1095-8274
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Necrotizing soft tissue infections (NSTIs) are the most severe and rapidly progressing class of skin and soft tissue infections (SSTIs). They are a surgical emergency and are associated with high mortality and morbidity. While NSTIs remain relatively rare, their incidence is steadily rising. Earlier diagnosis and more focused antibiotic treatments can potentially improve patient outcome, but both of these solutions require a more accurate understanding of the microbial component of these infections. While molecular detection methods, namely 16S sequencing, have not been traditionally used to identify the causative microorganisms in NSTIs, they are becoming more commonplace for other types of SSTIs, especially for chronic wound infections. In chronic wound infections, 16S sequencing has revealed a higher than previously detected prevalence of obligate anaerobes. Therefore, it is possible that 16S sequencing may also detect a higher than expected proportion of obligate anaerobes in NSTIs. In this review, we discuss the current state of knowledge concerning the diagnosis and treatment of NSTIs and present reasons why the role of anaerobes may be significantly underestimated.
[Mh] Termos MeSH primário: Bactérias Anaeróbias/isolamento & purificação
Dermatopatias Bacterianas/microbiologia
Infecções dos Tecidos Moles/microbiologia
[Mh] Termos MeSH secundário: DNA Ribossômico/química
DNA Ribossômico/genética
Seres Humanos
Incidência
Técnicas de Diagnóstico Molecular/métodos
RNA Ribossômico 16S/genética
Análise de Sequência de DNA
Dermatopatias Bacterianas/diagnóstico
Dermatopatias Bacterianas/epidemiologia
Infecções dos Tecidos Moles/diagnóstico
Infecções dos Tecidos Moles/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (DNA, Ribosomal); 0 (RNA, Ribosomal, 16S)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  6 / 3455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468217
[Au] Autor:Jeong YJ; Suh HW; Shim HS
[Ad] Endereço:Department of Plastic and Reconstructive Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.
[Ti] Título:Cervicofacial Primary Cutaneous Actinomycosis: Surgical Treatment for Complete Remission of the Disease.
[So] Source:J Craniofac Surg;28(3):e269-e271, 2017 May.
[Is] ISSN:1536-3732
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Actinomycosis, an infectious bacterial disease caused by Actinomyces species, is very rare and is characterized by contiguous spreading, subacute to chronic granulomatous inflammation and the formation of multiple abscesses and sinus tracts that may discharge sulfur granules. Actinomycosis that presents on the skin without endogenous origin is called primary cutaneous actinomycosis, and the occurrence and treatment of primary cutaneous actinomycosis is rarely reported. This report describes the treatment of primary cervicofacial actinomycosis with a literature review, and emphasizes the importance of surgical option for complete remission of the disease.
[Mh] Termos MeSH primário: Actinomyces/isolamento & purificação
Actinomicose Cervicofacial/cirurgia
Procedimentos Cirúrgicos Dermatológicos/métodos
Dermatopatias Bacterianas/cirurgia
[Mh] Termos MeSH secundário: Actinomicose Cervicofacial/diagnóstico
Actinomicose Cervicofacial/microbiologia
Idoso
Biópsia
Feminino
Seres Humanos
Indução de Remissão
Pele/diagnóstico por imagem
Pele/microbiologia
Dermatopatias Bacterianas/diagnóstico
Dermatopatias Bacterianas/microbiologia
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180126
[Lr] Data última revisão:
180126
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1097/SCS.0000000000003518


  7 / 3455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29284252
[Au] Autor:Pérez-Tanoira R; Ramos JM; Prieto-Pérez L; Tesfamariam A; Balcha S; Tissiano G; Cabello A; Cuadros J; Rodríguez-Valero N; Barreiro P; Reyes F; Górgolas M
[Ad] Endereço:Gambo Rural General Hospital, Kore, West-Arsi, Gambo, Ethiopia. ramontanoira@hotmail.com.
[Ti] Título:Diagnosis of cutaneous anthrax in resource-poor settings in West Arsi Province, Ethiopia.
[So] Source:Ann Agric Environ Med;24(4):712-715, 2017 Dec 23.
[Is] ISSN:1898-2263
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Cutaneous anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis, which typically presents with ulcers after contact with animals or animal products, and is rarely seen in high-income countries but is common in those with low- and middle-incomes. Objective. The aim of this study is to show the main clinical characteristics of cutaneous anthrax in endemic areas. MATERIAL AND METHODS: The study describes the main clinical characteristics of cutaneous anthrax in eight patients (six female and two male, age range 1 - 56 years) admitted to the rural General Hospital of Gambo, West Arsi Province of Ethiopia from 2010-2013. RESULTS: In all cases, lesions began as an erythematous papule located on exposed sites (n=7 head; n=1 thigh) and subsequently became a necrotic black eschar surrounded by an edematous halo. Two patients presented with painful ipsilateral adenopathy near the black eschar. Four patients developed a malignant pustule on the suborbital region of the face. Patients responded positively to treatment, and the lesions resolved, leaving eschars. However, one patient suffered the loss of an eyeball, and another died 12 hours after starting treatment. CONCLUSIONS: Physicians working in rural areas of resource-poor settings should be trained in the clinical identification of cutaneous anthrax. Early antibiotic treatment is essential for decreasing morbidity and mortality.
[Mh] Termos MeSH primário: Antraz/diagnóstico
Bacillus anthracis/fisiologia
Dermatopatias Bacterianas/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Antraz/tratamento farmacológico
Antraz/epidemiologia
Antraz/microbiologia
Antibacterianos/administração & dosagem
Bacillus anthracis/efeitos dos fármacos
Bacillus anthracis/genética
Bacillus anthracis/isolamento & purificação
Criança
Pré-Escolar
Etiópia/epidemiologia
Feminino
Seres Humanos
Lactente
Masculino
Meia-Idade
População Rural
Dermatopatias Bacterianas/tratamento farmacológico
Dermatopatias Bacterianas/epidemiologia
Dermatopatias Bacterianas/microbiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171230
[St] Status:MEDLINE


  8 / 3455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29046006
[Au] Autor:Jenssen C; Schwede I; Neumann V; Pietsch C; Handrick W
[Ad] Endereço:Krankenhaus Märkisch Oderland, Akademisches Lehrkrankenhaus der Medizinischen Hochschule Brandenburg "Theodor Fontane", Klinik für Innere Medizin, Strausberg.
[Ti] Título:[Skin and Soft Tissue Infections Due to Corynebacterium ulcerans - Case Reports].
[Ti] Título:Haut- und Weichteilinfektionen durch Corynebacterium ulcerans ­ Fallberichte..
[So] Source:Dtsch Med Wochenschr;142(21):1609-1612, 2017 Oct.
[Is] ISSN:1439-4413
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:We report on three patients suffering from skin and soft tissue infections of the legs due to toxigenic Corynebacterium ulcerans strains. In all three patients, there was a predisposition due to chronic diseases. Three patients had domestic animals (cat, dog) in their households. A mixed bacterial flora including Corynebacterium ulcerans was found in wound swab samples. Diphtheric toxin was produced by the Corynebacterium ulcerans strains in all three cases. In all three patients, successful handling of the skin and soft tissue infections was possible by combining local treatment with antibiotics. Diphtheria antitoxin was not administered in any case. Based on a review of the recent literature pathogenesis, clinical symptoms and signs, diagnostics and therapy of skin and soft tissue infections due to Corynebacterium ulcerans are discussed. Corynebacterium ulcerans should be considered as a potential cause of severe skin and soft tissue infections. Occupational or domestic animal contacts should be evaluated.
[Mh] Termos MeSH primário: Infecções por Corynebacterium/microbiologia
Dermatopatias Bacterianas/microbiologia
Infecções dos Tecidos Moles/microbiologia
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Animais
Animais Domésticos
Toxinas Bacterianas/biossíntese
Corynebacterium/classificação
Corynebacterium/metabolismo
Infecções por Corynebacterium/complicações
Infecções por Corynebacterium/diagnóstico
Infecções por Corynebacterium/terapia
Feminino
Seres Humanos
Masculino
Meia-Idade
Dermatopatias Bacterianas/complicações
Dermatopatias Bacterianas/diagnóstico
Dermatopatias Bacterianas/terapia
Infecções dos Tecidos Moles/complicações
Infecções dos Tecidos Moles/diagnóstico
Infecções dos Tecidos Moles/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Toxins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171019
[St] Status:MEDLINE
[do] DOI:10.1055/s-0043-117929


  9 / 3455 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28988505
[Au] Autor:Bassetti M; Pecori D; Cojutti P; Righi E; Pea F
[Ad] Endereço:a Infectious Diseases Clinic, Department of Medicine , University of Udine and Azienda Sanitaria Universitaria Integrata di Udine , Udine , Italy.
[Ti] Título:Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections.
[So] Source:Expert Opin Drug Metab Toxicol;13(11):1193-1200, 2017 Nov.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: In the era of multi-drug resistant pathogens, the adequate treatment of skin and skin structure infections remains a challenge for clinicians. Delafloxacin, with its broad spectrum against Gram-positive, Gram-negative and anaerobic organisms, represents a new therapeutic option in this setting, especially when coverage of methicillin-resistant Staphylococcus aureus is required in the empirical or targeted approach. Areas covered: In this drug evaluation, the Authors have reviewed the pharmacokinetic and pharmacodynamic characteristics of delafloxacin. In addition, recent data on clinical efficacy and safety from clinical trials have been included. Expert opinion: Delafloxacin represents an attractive therapeutic option due to a broad antimicrobial and favorable pharmacokinetic and pharmacodynamic profile. Several in vitro studies have demonstrated the low potential for resistance selection if used in empirical regimens. Delafloxacin is a promising candidate for the treatment of Gram-positive infections, especially if co-infection with other pathogens is suspected. This is because of the very low MIC of the agent for Gram-positive (including MRSA) and anaerobic bacteria and because of the wide spectrum of activity against Gram-negative organisms. For these interesting microbiological and PK/PD characteristics we expect future uses of this drug in other indications such as diabetic foot infection, osteomyelitis, prosthetic joint infections, abdominal infections and central nervous system infections.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Fluoroquinolonas/uso terapêutico
Dermatopatias Bacterianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antibacterianos/efeitos adversos
Antibacterianos/farmacocinética
Farmacorresistência Bacteriana Múltipla
Fluoroquinolonas/efeitos adversos
Fluoroquinolonas/farmacocinética
Bactérias Gram-Negativas/efeitos dos fármacos
Infecções por Bactérias Gram-Negativas/tratamento farmacológico
Infecções por Bactérias Gram-Negativas/microbiologia
Bactérias Gram-Positivas/efeitos dos fármacos
Infecções por Bactérias Gram-Positivas/tratamento farmacológico
Infecções por Bactérias Gram-Positivas/microbiologia
Seres Humanos
Testes de Sensibilidade Microbiana
Dermatopatias Bacterianas/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Fluoroquinolones); 6315412YVF (delafloxacin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171010
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2017.1386654


  10 / 3455 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28918832
[Au] Autor:Fazili T; Riddell S; Kiska D; Endy T; Giurgea L; Sharngoe C; Javaid W
[Ad] Endereço:Division of Infectious Disease, Upstate Medical University, Syracuse, NY. Electronic address: fazilit@upstate.edu.
[Ti] Título:Streptococcus anginosus Group Bacterial Infections.
[So] Source:Am J Med Sci;354(3):257-261, 2017 Sep.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The Streptococcus anginosus group (SAG) causes a variety of infections in adults. To better understand the burden of SAG infections and their associated morbidity and mortality, we conducted a retrospective analysis of these infections in adults at a tertiary care center. METHODS: A retrospective review of all cultures positive for SAG in adults and a corresponding review of the patients' medical records were conducted at a tertiary care facility in central New York. Patients with these cultures during the period of January 2007-December 2011 were included. Demographic data, area of residence, clinical features and underlying illnesses, site of infection, length of hospital stay, antibiotic susceptibility and antibiotic therapy were recorded and analyzed. RESULTS: There were 332 SAG cases; most patients were males (59%), mean age of 47 years and 84% lived in urban areas. Overall mortality was 3% with underlying conditions common such as diabetes (25%), hypertension (31%) and immunodeficiency (22%). Most of the infections were related to skin and soft tissue (72%) and polymicrobial (70%) with gram-negative anaerobes and Enterobacteriaceae commonly isolated with SAG. CONCLUSIONS: We present the largest study, thus far, reviewing the clinical presentation, management and outcome of infections due to the SAG of organisms. Notable findings from our study are the low mortality associated with SAG infection, and the propensity to present as a skin and tissue and polymicrobial infection. Our findings will assist clinicians in managing patients with SAG infections and recognizing that S anginosus may be one of several organisms responsible for infection.
[Mh] Termos MeSH primário: Dermatopatias Bacterianas/microbiologia
Infecções dos Tecidos Moles/microbiologia
Infecções Estreptocócicas/microbiologia
Streptococcus anginosus/isolamento & purificação
[Mh] Termos MeSH secundário: Adulto
Antibacterianos/administração & dosagem
Antibacterianos/uso terapêutico
Desbridamento
Feminino
Seres Humanos
Tempo de Internação
Masculino
Testes de Sensibilidade Microbiana
Meia-Idade
New York/epidemiologia
Estudos Retrospectivos
Dermatopatias Bacterianas/mortalidade
Dermatopatias Bacterianas/terapia
Infecções dos Tecidos Moles/mortalidade
Infecções dos Tecidos Moles/terapia
Infecções Estreptocócicas/mortalidade
Infecções Estreptocócicas/terapia
Streptococcus anginosus/patogenicidade
Centros de Atenção Terciária
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170919
[St] Status:MEDLINE



página 1 de 346 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde